

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobulin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

NCT06705062

Status	RECRUITING
Phase	Phase 3
Sponsor	Shanghai Jiao Tong University School of Medicine
Enrollment	316 participants

Key Eligibility Criteria

Inclusion (5)

- patients undergo allo-HSCT with matched unrelated donor or haplo-identical donor;
- normal organ function (creatinine clearance ≥ 50 ml/min/1.73m² or creatinine ≤ 2 mg/dl (or 177μ mol/L); no hepatic abnormal (ALT or AST $\leq 2.5 \times N$; TBil $\leq 1.5 \times N$); Normal pulmonary function (FEV1 FVC DLCO $\geq 80\%$); normal cardiac function (EFS $\geq 50\%$);
- ECOG: 0-2;
- Life expectation ≥ 3 months;
- Informed consent provided.

Exclusion (4)

- Pregnancies
- active hepatitis (HBV-DNA $\geq 1 \times 10^3$ copies/ml);
- active infection require anti-biotics;
- HIV infection

Locations (1 total)

Ruijin hospital, Shanghai, Shanghai Municipality, China